Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open Phase Ib/II Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-8080 in Combination With Dalpiciclib Isethionate Tablets in Patients With ER-positive, HER2-negative Unresectable or Metastatic Breast Cancer

NCT06167694 is registered in ClinicalTrials.gov with Shandong Suncadia Medicine Co., Ltd. as lead sponsor.

NCT NCT06167694
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06167694 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open Phase Ib/II Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-8080 in Combination With Dalpiciclib Isethionate Tablets in Patients With ER-positive, HER2-negative Unresectable or Metastatic Breast Cancer
Lead sponsor
Shandong Suncadia Medicine Co., Ltd.
Phase
Phase 1/2
Overall status
Recruiting
Start date
December 20, 2023
Completion date
June 30, 2026
Enrollment
146 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

unresectable or metastatic breast cancer